INT79181

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.06
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 7
Disease Relevance 2.23
Pain Relevance 0.80

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (GP1BA) plasma membrane (GP1BA)
Anatomy Link Frequency
blood 1
chest 1
GP1BA (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 1 97.80 Very High Very High Very High
Angina 13 97.68 Very High Very High Very High
headache 18 86.24 High High
withdrawal 6 81.40 Quite High
aspirin 3 25.00 Low Low
cva 2 25.00 Low Low
Disease Link Frequency Relevance Heat
Respiratory Sounds 36 98.68 Very High Very High Very High
Angina 12 97.68 Very High Very High Very High
Dyspnea 12 96.40 Very High Very High Very High
Cv General 3 Under Development 1 94.60 High High
Bronchitis 126 91.96 High High
Thrombocytopenia 2 90.04 High High
Headache 18 86.24 High High
Vomiting 12 85.04 High High
Emergencies 6 58.92 Quite High
Pulmonary Disease 12 34.28 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The mean decrease in the individual BSS‘coughing’, ‘sputum’, ‘pulmonary rales at auscultation’, ‘chest pain while coughing’ and ‘dyspnoea’ from day 0 to day 7 was markedly more pronounced in the EPs 7630 (60 mg) and EPs 7630 (90 mg) groups than in the placebo group.
Negative_regulation (decrease) of individual BSS in chest associated with angina, respiratory sounds and dyspnea
1) Confidence 0.06 Published 2010 Journal Acta Paediatrica (Oslo, Norway : 1992) Section Body Doc Link PMC2855831 Disease Relevance 0.36 Pain Relevance 0.10
Secondary efficacy variables were: treatment response according to three criteria (BSS total score of <3 on day 7, decrease in BSS total score of at least 7 points from day 0 to day 7 and BSS total score <3 on day 7 combined with a decrease in BSS total score of at least 7 points from day 0 to day 7), onset of effect, change in the total score of individual symptoms and, change of general symptoms (e.g.
Negative_regulation (decrease) of BSS total score
2) Confidence 0.06 Published 2010 Journal Acta Paediatrica (Oslo, Norway : 1992) Section Body Doc Link PMC2855831 Disease Relevance 0.56 Pain Relevance 0.17
The decrease in the BSS total score between day 0 and day 7 was more pronounced in the active treatment groups compared with that in the placebo group [placebo: 3.3 ± 2.6, EPs 7630 (30 mg): 3.6 ± 2.4, EPs 7630 (60 mg): 4.4 ± 2.4, EPs 7630 (90 mg): 5.0 ± 1.9].
Negative_regulation (decrease) of BSS total score
3) Confidence 0.06 Published 2010 Journal Acta Paediatrica (Oslo, Norway : 1992) Section Body Doc Link PMC2855831 Disease Relevance 0 Pain Relevance 0.04
Secondary efficacy variables were: treatment response according to three criteria (BSS total score of <3 on day 7, decrease in BSS total score of at least 7 points from day 0 to day 7 and BSS total score <3 on day 7 combined with a decrease in BSS total score of at least 7 points from day 0 to day 7), onset of effect, change in the total score of individual symptoms and, change of general symptoms (e.g.
Negative_regulation (decrease) of BSS total score
4) Confidence 0.06 Published 2010 Journal Acta Paediatrica (Oslo, Norway : 1992) Section Body Doc Link PMC2855831 Disease Relevance 0.56 Pain Relevance 0.16
The subsequent pairwise comparisons of each active treatment group with placebo using the ANCOVA model revealed statistically significant differences in the decrease in the BSS total score for the EPs 7630 60 mg and 90 mg groups (p = 0.0004 and p < 0.0001 respectively, two-sided ANCOVA p-values).
Negative_regulation (decrease) of BSS total score
5) Confidence 0.05 Published 2010 Journal Acta Paediatrica (Oslo, Norway : 1992) Section Body Doc Link PMC2855831 Disease Relevance 0 Pain Relevance 0.03
Secondary efficacy variables were: treatment response according to three criteria (BSS total score of <3 on day 7, decrease in BSS total score of at least 7 points from day 0 to day 7 and BSS total score <3 on day 7 combined with a decrease in BSS total score of at least 7 points from day 0 to day 7), onset of effect, change in the total score of individual symptoms and, change of general symptoms (e.g.
Negative_regulation (decrease) of BSS total score
6) Confidence 0.05 Published 2010 Journal Acta Paediatrica (Oslo, Norway : 1992) Section Body Doc Link PMC2855831 Disease Relevance 0.56 Pain Relevance 0.16
GPIb-IIIa receptor blockade and membrane glycoproteins were evaluated with immunological markers in venous blood samples taken before. 10, 24, 48, 72, and 96 h after initial treatment with either abciximab or heparin.
Negative_regulation (blockade) of GPIb-IIIa receptor in blood
7) Confidence 0.00 Published 1998 Journal Thromb. Haemost. Section Abstract Doc Link 9869173 Disease Relevance 0.18 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox